FinnCap reaffirmed their corporate rating on shares of Premaitha Health (LON:NIPT) in a research report report published on Monday.

Premaitha Health (LON:NIPT) opened at GBX 5.38 ($0.07) on Monday. Premaitha Health has a 12-month low of GBX 4.05 ($0.05) and a 12-month high of GBX 14.40 ($0.19).

ILLEGAL ACTIVITY WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at

About Premaitha Health

Premaitha Health PLC is engaged in molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease. The Company’s product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated non-invasive prenatal test in-house.

Receive News & Ratings for Premaitha Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Premaitha Health and related companies with's FREE daily email newsletter.